About Daiichi Sankyo
Daiichi Sankyo is a publicly listed company based in Tokyo (Japan) founded in 2005. Pharmaceutical drugs are developed to address diverse medical needs. The company has 19,770 employees. Daiichi Sankyo has completed 3 acquisitions, including Ambit Biosciences, Luitpold and Plexxikon. Its chief executive, as recorded, is Sunao Manabe. Its website daiichisankyo.com draws about 72 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
The company was founded in 2005 and is headquartered in Tokyo, Japan. Operations center on the pharmaceutical sector, where drugs are developed for oncology, cardiovascular conditions, migraine, diabetes, and other therapeutic areas. Enhertu, a HER2-directed antibody-drug conjugate, is provided for breast cancer treatment. Additional products target various unmet medical requirements globally.
- Headquarters Tokyo, Japan
- Employees 19,770
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website daiichisankyo.com
- Social LinkedIn X Facebook
- Legal Name Daiichi Sankyo Company, Limited
- Annual Revenue$13.29 B (USD)12.55as on Mar 31, 2026
- Net Profit$1.75 B (USD)-5.42as on Mar 31, 2026
- EBITDA$2.13 B (USD)-10.09as on Mar 31, 2026
- Latest Funding Round$236.45K (USD), Grant
Sep 2021
- Investors
- Employee Count19,770
- Investments & AcquisitionsAmbit Biosciences
& 2 more
Funding Insights of Daiichi Sankyo
- Total Rounds 1
- Last Round Grant — $236,453
- First Round $236,453
(Sep 2021)
- Investors Count 1
All 1 funding rounds of Daiichi Sankyo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $236,453 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Daiichi Sankyo
Daiichi Sankyo has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GrandEst.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Access and development services for government programs are provided. | 2008 | grandest.fr | Strasbourg, France |
Investor details for Daiichi Sankyo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Daiichi Sankyo
272 people are tracked at Daiichi Sankyo (164 in leadership, 2 in board & advisors, 106 in team); the tracked headcount is 19,770.
| Name | Role | Group |
|---|---|---|
Sunao Manabe | CEO | Leadership |
George Nakayama | CEO | Leadership |
Cole D. | Associate Director - US Forecasting & Business Analytics | Leadership |
Julie Jeanes | Vice President, Global Team Leader | Leadership |
Brian Kiesel | Associate Director | Leadership |
Hyewon Youm | Associate Director, R&d Procurement | Leadership |
Nipa Patel | Associate Director, Trial Feasibility & Site Intelligence | Leadership |
Sebastiano Gattoni-Celli | Senior Director, Clinical Development Oncology | Leadership |
Ken Keller | Chairman, President & CEO | Leadership |
Ken Takeshita | Global Head of Research & Development | Leadership |
Tzuyung Douglas Kou | Executive Director, Head Of Epidemiology, Clinical Safety And Pharmacovigilance | Leadership |
Ruth Abrams | Associate Director | Leadership |
Dana Cedeno | Director Of Clinical Operations | Leadership |
Takahiro Nagayama | Head Of Research Institute Boston | Leadership |
Casey Davis | Director | Leadership |
Angie Sim | Head Of Global Pharmacovigilance/medical Affairs QA | Leadership |
Mai Nguyen | Associate Director, Clinical Science | Leadership |
Maria Lizza Bowen | Global Head Of Protocol Excellence, Sr. Director, Clinical Science | Leadership |
Meg Lindsay | Executive Director | Leadership |
James Kerwin | Executive Director | Leadership |
252 more people are available in the full profile.
Complete people profiles for Daiichi Sankyo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Daiichi Sankyo
Daiichi Sankyo is a publicly listed company on the TSE with ticker symbol 4568 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Sep 2005
- Listed onTSE: 4568
- Listed entityDaiichi Sankyo Company, Limited
- Exchange sectorHealth technology
- ISINJP3475350009
- Share price2,601.00 JPY (-1.33% on the day) · 2026-10-14
- Market capitalisation4,796,605,830,566.00 JPY
- Price to earnings18.2
- EPS (diluted, trailing year)142.76 JPY
- Dividend yield3.38%
- Volume (last session)9,689,700
Financials of Daiichi Sankyo
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2,120.00B JPY | 279.73B JPY | 339.31B JPY |
| 2024 | 1,890.00B JPY | 295.76B JPY | 377.39B JPY |
| 2023 | 1,600.00B JPY | 200.73B JPY | 250.24B JPY |
| 2022 | 1,280.00B JPY | 109.19B JPY | 189.61B JPY |
| 2021 | 1,040.00B JPY | 66.97B JPY | 150.18B JPY |
Detailed financial statements for Daiichi Sankyo
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Daiichi Sankyo
Daiichi Sankyo has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Ambit Biosciences, Luitpold and Plexxikon.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Kinase inhibitors for cancer and immune disorders were developed. | ambitbio.com | San Diego, United States | 2000 | Sep 2014 | $315M | |
Develops small molecule pharmaceuticals for oncology, CNS and autoimmune diseases | plexxikon.com | Berkeley, United States | 2000 | Feb 2011 | $805M | |
Traditional pharma company engaged in development and marketing of variety of pharmaceutical products and medical devices | luitpold.com | New York, United States | 1910 | Jun 1990 | •••• |
Complete acquisition details for Daiichi Sankyo
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Daiichi Sankyo
6 dated milestones of Daiichi Sankyo across 31 years, from founding to its latest funding, stage changes and deals.
- Acquisition Acquires Luitpold.
- Founded Daiichi Sankyo is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Plexxikon.
- Acquisition Acquires Ambit Biosciences.
- Funding First funding round of $236K.
Web traffic of Daiichi Sankyo
The website of Daiichi Sankyo (daiichisankyo.com) receives about 72.3K visits a month and ranks #682,883 among all websites worldwide, #763 in Biotechnology and Pharmaceuticals.
- Monthly visits72.3K
▲ 53.4% vs previous month
- Unique visitors20.9K
per month
- Global rank#682,883
among all websites
- Category rank#763
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.0
- Average visit51 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Daiichi Sankyo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
daiichi-sankyo.eu | daiichi-sankyo.eu | 100% | #1,229,511 | – | |
| ds-pharma.com | 100% | View details | |||
dsi.com | dsi.com | 100% | – | ||
daiichi-sankyo.de | daiichi-sankyo.de | 96% | #4,386,230 | – | |
| takeda.com | 95% | 620.1K | #93,966 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Daiichi Sankyo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Daiichi Sankyo
Complete news archive for Daiichi Sankyo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daiichi Sankyo
Daiichi Sankyo was founded in 2005 and raised its 1st funding round 16 years after it was founded.
Daiichi Sankyo is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Sunao Manabe is the CEO of Daiichi Sankyo, as recorded in our data.
Daiichi Sankyo has 19,770 employees.
Annual revenue of Daiichi Sankyo is $13.29B as on Mar 31, 2026.
The company was founded in 2005 and is headquartered in Tokyo, Japan. Operations center on the pharmaceutical sector, where drugs are developed for oncology, cardiovascular conditions, migraine, diabetes, and other therapeutic areas. Enhertu, a HER2-directed antibody-drug conjugate, is provided for breast cancer treatment. Additional products target various unmet medical requirements globally.
Yes, Daiichi Sankyo is publicly traded on TSE under the ticker symbol 4568.
Daiichi Sankyo has made 3 acquisitions, including Ambit Biosciences, Luitpold, and Plexxikon.
Daiichi Sankyo has 1 investor. Key investors include GrandEst.